Other Mutations: ATM

NCT05128825: A Study of ZN-c3 in Subjects With Malignant Tumors

NCT05128825
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations, ATM, ATR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior therapy of ZN-c3 or any other WEE1 inhibitor
https://ClinicalTrials.gov/show/NCT05128825

NCT05071209: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

NCT05071209
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations, ATM, ATR, BRCA+, CDK, MMR, POLD
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patients must be 21 years of age or younger to be eligible for Part B, and 17 years of age or younger for Part A
Exclusions: Patients with prior exposure to BAY 1895344 (elimusertib) or any other specific ATR inhibitors including berzosertib (M6620, VX-970), ceralasertib (AZD6738), M4344 (VX-803), M1774, and RP-3500; Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05071209

Up ↑